Correlation of Somatic Mutation and Expression Identifies Genes Important in Human Glioblastoma Progression and Survival

David L. Masica and Rachel Karchin

Abstract

Cooperative dysregulation of gene sequence and expression may contribute to cancer formation and progression. The Cancer Genome Atlas (TCGA) Network recently catalogued gene sequence and expression data for a collection of glioblastoma multiforme (GBM) tumors. We developed an automated, model-free method to rapidly and exhaustively examine the correlation among somatic mutation and gene expression and interrogated 149 GBM tumor samples from the TCGA. The method identified 41 genes whose mutation status is highly correlated with drastic changes in the expression (z-score $\geq 2.0$), across tumor samples, of other genes. Some of the 41 genes have been previously implicated in GBM pathogenesis (e.g., NF1, TP53, RB1, and IDH1) and others, while implicated in cancer, had not previously been highlighted in studies using TCGA data (e.g., SYNE1, KLF6, FGFR4, and EPHB4). The method also predicted that known oncogenes and tumor suppressors participate in GBM via drastic over- and underexpression, respectively. In addition, the method identified a known synthetic lethal interaction between TP53 and PLK1, other potential synthetic lethal interactions with TP53, and correlations between IDH1 mutation status and the overexpression of known GBM survival genes.

Cancer Res; 71(13); 4550–61. ©2011 AACR.

Introduction

Cancer is a complex disease arising from the concerted effect of multiple (epi)genetic changes that yield pathway dysregulation via alterations in gene copy number, DNA methylation, gene expression, and molecular function (1–3). Specific combinations of these alterations can vary, even in histologically similar cancers. Until recently, the limited scalability of genetic experiments forbade complete characterization of these complexities and variances; now, large-scale cancer genomics experiments can catalogue alterations with up to full-exome coverage across tens to hundreds of samples (1, 2, 4). Bioinformatics techniques can interrogate this data and identify alterations that cooperatively drive cancer (5–10), even with patient specificity (6).

Alterations that affect gene expression levels [e.g., copy number alteration (CNA) and DNA methylation] in cancer genomes have been used to identify driver genes and molecular subtypes of a particular cancer (11, 12). Such alterations have identified oncogenes activated via increased expression [as can occur with epidermal growth factor receptor (EGFR), for instance] or tumor suppressors deactivated via decreased expression (as can occur with RB1, for instance). Verhaak and colleagues showed that 4 clinically relevant glioblastomas [glioblastoma multiforme (GBM)] subtypes could be defined using a subset of The Cancer Genome Atlas (TCGA) GBM expression data (11). In that study, the authors also grouped mutation and CNA with the expression-defined GBM subtypes. Increased expression can further be used to identify cancer-specific essential genes, oncogene addiction, and synthetic lethality (13, 14).

Understanding subtype and patient-specific combinatorial patterns of (epi)genetic alterations in tumors has promise to inform therapeutic regimens. First, expression patterns common to a subtype may be informative with respect to the drugs most suitable for a group of patients. For example, the neural GBM subtype has a high rate of EGFR and ERBB2 overexpression, but patients with neural GBM that are not EGFR and/or ERBB2 positive may not benefit from receptor tyrosine kinase inhibitors. Second, alterations in off-target genes can modulate the efficacy of targeted therapies (i.e., drug resistance). For instance, EGFR-positive tumors respond to gefitinib, but amplification of the MET proto-oncogene can cause resistance (15). Tumors overexpressing ERBB2 respond to trastuzumab, but phosphoinositide-3-kinase (PI3K) mutation can cause trastuzumab resistance (15). Finally, cancer-specific essential
genes, oncogene addiction, and synthetic lethality can be druggable vulnerabilities in tumors (13, 14). Notably, while current methods for synthetic lethal screening can identify such vulnerabilities, some studies suggest that considering isolated pairwise interactions limits generalizability. For example, 3 groups screened unique KRAS-driven cancers for synthetic lethal interactions and recovered 3 unique lists of genes synthetic lethal with KRAS mutation (16); this suggests that the identified synthetic lethal interactions were a subset of larger, more complex networks (i.e., context specificity).

Many current bioinformatics approaches for assessing complex patterns of (epi)genetic aberrations in cancer rely on pre-existing knowledge of gene annotations, gene sets, protein–protein interactions, and curated pathways. Gene set enrichment analysis is a widely used method for interpreting differential gene expression levels, based on previously described functions and pathway memberships. Vaske and colleagues have used CNA and expression data to infer patient-specific pathway activities in TCGA GBM samples (6). In that report, the authors identified GBM subtypes using pathways inferred from the National Cancer Institute-Nature Pathway Interaction Database.

Here, we present a new approach to identify genes that tumors require for progression and survival, with patient-level specificity, by exhaustively and rapidly detecting correlations among gene expression and mutation. The method makes inferences directly from a collection of cancer genome samples and does not depend on pre-existing knowledge of gene function or interactions. We propose that this unbiased approach has utility to complement the findings of current gene set and pathway-based methods. We apply the method to examine the correlation between expression and mutation in TCGA GBM tumor samples. Our results suggest that this approach can be useful for identifying genes that participate in cancer progression, networks of genes that promote cancer via combined genetic and transcriptome alterations, druggable cancer-specific genes, and synthetic lethal interactions.

Materials and Methods

We developed a novel computational method to identify genes potentially important in tumorigenesis and cancer-specific survival genes from correlations among somatic mutation and expression in cancer genomics data (Fig. 1). The algorithm compares the sample (patient)-specific mutation status of each gene with the expression level of each gene, across all tumor samples. Genes with drastic mutation-correlated differential expression, and the corresponding mutated genes, are returned for analysis. The algorithm also identifies statistically significant mutation–mutation coincidence and mutual exclusivity. Gene networks are constructed containing all significant correlations and automated literature searches are used to illuminate clinically relevant findings. Findings presented here were identified using all TCGA GBM samples for which expression and mutation data were available and have a value of $P < 0.01$ and a false discovery rate (FDR) of less than 0.05.

Algorithm

We begin by building 2 matrices, 1 expression and 1 mutation, which are gene (row) by sample (column; Fig. 1A). At this stage, the expression matrix is populated by the factored, 3-platform data (see Data) and the mutation matrix is binary: 1 (true) if any mutation (see Data) occurs in a particular gene in a particular sample, otherwise the element is 0 (false).

Next, 2-class, unpaired Significance Analysis of Microarrays (SAM; ref. 17) is used to find genes that are differentially expressed with respect to the mutation status of a particular gene across all samples (i.e., the 2 classes are defined by the binary mutation vector for that particular gene from the mutation matrix; Fig. 1B). SAM was employed using a moderated $t$-statistic and the random seed was set to a constant ($\text{rand} = 123$) for reproducibility. To correct for multiple testing, 100 random permutations of the class labels were made and a cutoff FDR of 0.05 applied. Genes with an FDR of less than 0.05 are considered to have significant mutation-correlated differential expression and are passed to the next stage of the algorithm.

Next, an expression matrix is created, this time only containing genes deemed to have significant mutation-correlated differential expression in the previous step. Then, the matrix is converted to 2 binary matrices (1 for significant overexpression and 1 for significant underexpression) with the following calculation: (i) The $z$-score for each expression matrix element is calculated with respect to that element’s row (i.e., gene specific); this is repeated for each row (gene). (ii) For the overexpressed binary matrix, any element with a $z$-score $> 2.0$ is 1 (true), otherwise the element is 0 (false); for the underexpressed binary matrix an element is 1 if the $z$-score $< -2.0$ and 0 otherwise (Fig. 1C). Then, Fisher’s exact $P$ value is calculated for each gene in the expression matrix by populating a $2 \times 2$ contingency table with a binary expression vector (category 1) and the mutation vector (category 2); this process is repeated for each binary expression vector from the binary expression matrix (Fig. 1D). This calculation allowed us to recover only genes that had drastic mutation-correlated over- and underexpression and to assign each correlation with an exact $P$ value. Mutation-correlated over- and underexpressed genes with a value of $P < 0.01$ (Fisher’s exact test) and an FDR of less than 0.05 (see Multiple Testing Correction) are hierarchically clustered using heatmap.2 from the R package, and mutations are plotted across the samples (Fig. 1E). The entire process is repeated once for each mutated gene.

Pairwise mutation–mutation correlation

Two-by-two contingency tables were constructed for every pairwise mutation vector to find significant ($P < 0.01$, Fisher’s exact test) mutational co-occurrence and mutual exclusivity. Coincident pairwise mutation in at least 3 samples was additionally required to declare significant mutational co-occurrence.
Multiple testing correction

For both mutation–mutation correlation and mutation-correlated over- and underexpression, a potential discovery is declared when Fisher’s exact value of \( P < 0.01 \). For each potential discovery, the algorithm makes 1,000 random permutations of the columns (samples) and counts the correlations inferred from the permuted data (i.e., false discoveries). If the calculated FDR is greater than 0.05, the potential discovery is rejected as false. Every correlation presented in this article has a Fisher’s exact value of \( P < 0.01 \) with an FDR less than 0.05.

Data

We obtained expression data for GBM samples at the TCGA web site (http://tcga-data.nci.nih.gov/docs/publications/gbm_exp/). These expression data were gathered on 3 individual microarray platforms, including Affymetrix Human Exon ST GeneChips, Affymetrix HT-HG-U133A GeneChips,
and custom-designed Agilent 244,000 feature gene expression microarrays (11). A single estimate of the relative expression for each gene in each sample was obtained using factor analysis (11). We removed any gene that had a missing value in any sample used for this study (reducing the total from 11,861 to 11,828).

We obtained phase I GBM sequence data from the TCGA web site (http://tcga-data.nci.nih.gov/tcga/). We obtained phase II GBM sequence data from the Baylor College of Medicine (David A. Wheeler, personal communication). All mutations labeled Validated and Nonsilent, and Somatic or LOH were used. There were a total of 583 genes that met these criteria and 149 samples for which both expression and mutation data were available.

**Literature mining**

All literature mining used to highlight results (Table 1) was automated to increase efficiency and reduce user bias. Importantly, the literature mining was used only to interpret results, not as an input to the algorithm. To highlight potentially important genes that were identified, the algorithm searched 2,438,505 abstracts and titles for PubMed keyword “cancer” and the gene of interest; the same procedure was carried out for 16,237 GBM-specific articles. To determine whether genes had been described in previous studies using TCGA GBM data, we downloaded references 5 to 12 and converted them to text for automated searching. All mutation-correlated overexpressed genes were cross-referenced with a list of known GBM survival genes (Table 2; ref. 18). We retrieved summaries from the Entrez Gene database; these summaries were used to determine whether mutation-correlated overexpressed genes were oncogenes and whether mutation-correlated underexpressed genes were tumor suppressors (Fig. 1F and Table 3).

The algorithm developed for this study was written in Python (Fig. 1). Entrez PubMed and Gene Summary database queries were made using Biopython. All calls to R and Bioconductor were made via the R interface for Python, RPy2 (http://rpy.sourceforge.net/rpy2.html). For the TCGA GBM data set used here, total algorithm running time was less than 5 hours on a Linux workstation (2-core, 1.86-GHz processor, and 4 GB of RAM).

**Supplementary data**

Supplementary data for this article include 6 supplementary files: SYNE1 and IDH1 survival analysis and occurrence of mutations highlighted in this study in the COSMIC database (Supplementary Fig. S1 and Supplementary Table S1); individual heatmaps for each of the 41 genes whose mutation status is significantly correlated with the over- and underexpression of other genes (Supplementary Heatmaps); the raw data, including P values, for every correlation returned by our algorithm (Supplementary mutation–expression correlation and Supplementary mutation–mutation correlation); the sample-specific mutation type (e.g., nonsense, splice site, frame shift) for each mutated gene highlighted in the study, the zygosity, and the CHASM predictions for each missense mutation (Supplementary Mutation type, zygosity, and score); legends for all spreadsheets (Supplementary Spreadsheet legends).

**Results and Discussion**

Table 1 shows statistics for all genes where mutation status is significantly correlated with the drastic over- or underexpression, across tumor samples, of other genes. Our clustering scheme required genes to be mutated in at least 2 samples, which reduced the total TCGA GBM set from 583 to 307. Forty-one of these mutated genes (~13%) were correlated with the drastic over- or underexpression of at least 2 of the 11,828 genes for which expression data were available. The low fraction of such correlations returned by our method partially reflects the stringency of the tests used to determine significance (see Materials and Methods). Comparing the numbers in columns 2 and 3 of Table 1 shows that there is no intrinsic bias of the algorithm to infer mutation-correlated over- or underexpression from frequency of mutation. For instance, HPN and IDH1 are each mutated in 11 samples, and IDH1 is correlated with the drastic over- or underexpression of 1.001 genes, whereas HPN is only correlated with the drastic over- or underexpression of 3 genes. Low-frequency mutations also show a distribution of correlated expression. In the case of mitogen-activated protein kinase (MAPK) 9, which was mutated in only 2 samples, there are 396 genes with correlated over- or underexpression. Conversely, CHL1 was mutated in 2 samples and only correlated with the differential expression of 2 genes.

If tumors select for genetic alterations that coordinate to promote cancer progression, then identifying coordinated genetic alterations could be useful to identify genes involved in tumorigenesis. Indeed, our approach identifies genes generally accepted to be involved in tumorigenesis (e.g., ATM, FGFR1, IDH1, MET, MSH6, NF1, RB1, and TP53). It is particularly difficult to assess the capacity of a genetic alteration to participate in cancer progression when that alteration is low frequency in the population; our approach identifies genes potentially involved in tumorigenesis that are mutated with low frequency in TCGA GBM tumor samples. For instance, ATM, KLF6, and LEMD3 are low-frequency mutations in TCGA GBM tumor samples and have completely overlapping comutation (P = 9 × 10^{-5} for each pairwise interaction, Fisher’s exact test). And, these low-frequency mutations are each highly correlated with the drastic over- or underexpression of 165 other genes. These observations suggest that ATM, KLF6, and LEMD3 may cooperatively promote tumorigenesis in some TCGA GBM samples.

EP300 and FGFR4, FBXW7 and FURIN, and EP400 and FN1 are also each exclusively comutated in TCGA GBM samples (Table 1). These 4 exclusively comutated sets of genes comprise 9 of the 41 mutated genes identified in this study (~22%), which may be unexpected. One potential explanation for this finding is that the mutant pairs have a specific epistatic relationship that is distinct from any of the mutations in isolation. A factor complicating the interpretation of the exclusively comutated sets is the occurrence of the of the so-called mutator phenotype. Each gene in the exclusively comutated sets is mutated in samples that are of the mutator phenotype, marked by higher-than-average mutation rates owing to mutation in mismatch repair genes. With the
Table 1. The 41 genes whose mutation status is correlated with drastic over- and underexpression of other genes

<table>
<thead>
<tr>
<th>Gene symbol</th>
<th>Mutations</th>
<th>Differentially expressed genes</th>
<th>PubMed hits for cancer</th>
<th>PubMed hits for glioblastoma</th>
<th>Previously highlighted in study using TCGA GBM data?</th>
</tr>
</thead>
<tbody>
<tr>
<td>AKR1C3</td>
<td>16</td>
<td>5</td>
<td>82</td>
<td>4</td>
<td>Yes</td>
</tr>
<tr>
<td>ANK1</td>
<td>3</td>
<td>2</td>
<td>9</td>
<td>0</td>
<td>No</td>
</tr>
<tr>
<td>ATM^a</td>
<td>2</td>
<td>165</td>
<td>2,175</td>
<td>20</td>
<td>Yes</td>
</tr>
<tr>
<td>KLF6^a</td>
<td>2</td>
<td>165</td>
<td>103</td>
<td>6</td>
<td>No</td>
</tr>
<tr>
<td>LEMD3^a</td>
<td>2</td>
<td>165</td>
<td>5</td>
<td>0</td>
<td>No</td>
</tr>
<tr>
<td>CHL1</td>
<td>2</td>
<td>2</td>
<td>15</td>
<td>0</td>
<td>No</td>
</tr>
<tr>
<td>ConsReg523</td>
<td>7</td>
<td>10</td>
<td>0</td>
<td>0</td>
<td>No</td>
</tr>
<tr>
<td>DST (dystonin)</td>
<td>12</td>
<td>14</td>
<td>14</td>
<td>0</td>
<td>No</td>
</tr>
<tr>
<td>EP300^c</td>
<td>2</td>
<td>8</td>
<td>155</td>
<td>0</td>
<td>No</td>
</tr>
<tr>
<td>FGFR4^c</td>
<td>2</td>
<td>8</td>
<td>139</td>
<td>4</td>
<td>No</td>
</tr>
<tr>
<td>EP400^c</td>
<td>3</td>
<td>6</td>
<td>9</td>
<td>0</td>
<td>No</td>
</tr>
<tr>
<td>FN1^c</td>
<td>3</td>
<td>6</td>
<td>58</td>
<td>2</td>
<td>No</td>
</tr>
<tr>
<td>EPHB4</td>
<td>3</td>
<td>149</td>
<td>104</td>
<td>0</td>
<td>No</td>
</tr>
<tr>
<td>FBXW7^d</td>
<td>2</td>
<td>259</td>
<td>109</td>
<td>4</td>
<td>No</td>
</tr>
<tr>
<td>FURIN^d</td>
<td>2</td>
<td>259</td>
<td>252</td>
<td>8</td>
<td>Yes</td>
</tr>
<tr>
<td>FGFR1</td>
<td>3</td>
<td>2</td>
<td>491</td>
<td>19</td>
<td>Yes</td>
</tr>
<tr>
<td>HPN (Hepsin)</td>
<td>11</td>
<td>3</td>
<td>82</td>
<td>1</td>
<td>No</td>
</tr>
<tr>
<td>IDH1</td>
<td>11</td>
<td>1,001</td>
<td>126</td>
<td>41</td>
<td>Yes</td>
</tr>
<tr>
<td>INHBC</td>
<td>3</td>
<td>2</td>
<td>5</td>
<td>0</td>
<td>No</td>
</tr>
<tr>
<td>KCNG1</td>
<td>3</td>
<td>8</td>
<td>0</td>
<td>0</td>
<td>No</td>
</tr>
<tr>
<td>LGALS3BP</td>
<td>3</td>
<td>4</td>
<td>54</td>
<td>1</td>
<td>No</td>
</tr>
<tr>
<td>LUM</td>
<td>3</td>
<td>8</td>
<td>6</td>
<td>0</td>
<td>No</td>
</tr>
<tr>
<td>MADD</td>
<td>10</td>
<td>15</td>
<td>18</td>
<td>0</td>
<td>No</td>
</tr>
<tr>
<td>MAPK9</td>
<td>2</td>
<td>396</td>
<td>2</td>
<td>0</td>
<td>No</td>
</tr>
<tr>
<td>MARK1</td>
<td>2</td>
<td>20</td>
<td>14</td>
<td>0</td>
<td>No</td>
</tr>
<tr>
<td>MET (c-met)</td>
<td>3</td>
<td>10</td>
<td>1,674</td>
<td>52</td>
<td>Yes</td>
</tr>
<tr>
<td>MKI67</td>
<td>27</td>
<td>2</td>
<td>7,866</td>
<td>218</td>
<td>No</td>
</tr>
<tr>
<td>MSH6</td>
<td>4</td>
<td>3</td>
<td>320</td>
<td>9</td>
<td>Yes</td>
</tr>
<tr>
<td>MYST4</td>
<td>3</td>
<td>2</td>
<td>11</td>
<td>0</td>
<td>No</td>
</tr>
<tr>
<td>NF1</td>
<td>19</td>
<td>10</td>
<td>1,916</td>
<td>41</td>
<td>Yes</td>
</tr>
<tr>
<td>NOS3</td>
<td>3</td>
<td>59</td>
<td>190</td>
<td>1</td>
<td>No</td>
</tr>
<tr>
<td>PI5</td>
<td>2</td>
<td>47</td>
<td>1</td>
<td>0</td>
<td>No</td>
</tr>
<tr>
<td>PTK2B</td>
<td>2</td>
<td>55</td>
<td>38</td>
<td>0</td>
<td>No</td>
</tr>
<tr>
<td>RB1</td>
<td>9</td>
<td>12</td>
<td>1,025</td>
<td>21</td>
<td>Yes</td>
</tr>
<tr>
<td>SRGAP1</td>
<td>2</td>
<td>5</td>
<td>5</td>
<td>0</td>
<td>No</td>
</tr>
<tr>
<td>STK36</td>
<td>3</td>
<td>2</td>
<td>4</td>
<td>0</td>
<td>No</td>
</tr>
<tr>
<td>SYNE1</td>
<td>10</td>
<td>543</td>
<td>5</td>
<td>0</td>
<td>No</td>
</tr>
<tr>
<td>TCF12</td>
<td>2</td>
<td>28</td>
<td>25</td>
<td>0</td>
<td>Yes</td>
</tr>
<tr>
<td>TP53</td>
<td>48</td>
<td>38</td>
<td>4,011</td>
<td>189</td>
<td>Yes</td>
</tr>
<tr>
<td>TRPM3</td>
<td>4</td>
<td>318</td>
<td>1</td>
<td>0</td>
<td>No</td>
</tr>
<tr>
<td>WISP1</td>
<td>2</td>
<td>2</td>
<td>39</td>
<td>0</td>
<td>No</td>
</tr>
</tbody>
</table>

NOTE: Gene symbol is the mutated gene, mutations indicates the number of samples harboring mutation in the mutated gene. Differentially expressed genes indicates the number of genes whose expression is correlated with the mutation status of the mutated gene. PubMed hits for "cancer" is the number of times the mutated gene appeared in the title or abstract for articles returned by search term "cancer" (2,438,505 total articles returned) and similarly for PubMed hits for "glioblastoma" (16,237 total articles returned). Previously highlighted in a study using TCGA GBM data indicates whether the mutated gene appeared anywhere in the text of references 5 to 12. ^a,b,c,d^Groups of exclusively comutated. See Materials and Methods for complete details.
exception of LEMD3, EP400, and FN1, all genes in the comu-
tated sets are well-studied cancer genes, and recurrence of
mutations in these genes highlights them as potentially
important in the progression of some gliomas. But, because
these mutations were found in samples displaying the mutator
phenotype, the possibility that some of them are passenger
mutations has to be considered.

Columns 3 to 5 of Table 1 are derived from automated
literature searches. Although automated literature mining can
be prone to false positives, large disparities among and within
rows of Table 1 can highlight potentially important genes that
can be investigated manually. For instance, KFL6 was found in
the title or abstract of 103 articles on cancer and 6 specifically
on GBM; however, KFL6 is a low-frequency mutation in TCGA
GBM tumor samples and has never been highlighted in a study
of TCGA GBM data. Manual investigation of PubMed IDs
returned by our method indicates that KFL6 is a well-studied
cancer gene (19, 20). KLF6 is a putative tumor suppressor that
mediates growth inhibition by overexpression of the cell-cycle
inhibitor CDKN1A (19). TCGA GBM samples contain at least 1
mutation in a previously reported KLF6 glioma mutation site
(S77; ref. 20). Similarly, EPHB4, FGFR4, FURIN, and NOS3 are all
thought to be important in cancer progression; these genes are
mutated with low frequency in TCGA GBM tumor samples
and not highlighted in previous studies using TCGA GBM data.

**TP53 network**

Figure 2 is a heatmap of genes whose over- or under-
expression is significantly correlated with TP53 mutation.
TP53 mutations clusters in 2 main groups on the right half
the heatmap, with a few smaller clusters and outliers
located among the samples. Aside from MDM2 (bottom
of Fig. 2), all genes in Figure 2 are overexpressed when TP53
is mutated. MDM2 is overexpressed when TP53 is wild
type (i.e., MDM2 overexpression is mutually exclusive with TP53
mutation).

**TP53** is a well-studied cancer gene, therefore method efﬁ-
cacy can be considered on the basis of its ability to capture
known correlations. For instance, MDM2 is a negative reg-

---

**Figure 2.** Hierarchical clustering of
genes whose drastic over- and
underexpression is correlated with
TP53 mutation status. Black bars
across the top of the heatmap
indicate samples harboring TP53
mutation.
ulator of tumor suppressor TP53, therefore MDM2 overexpression and TP53 mutation can have a redundant phenotype and can be mutually exclusive (21); our method recovers this mutual exclusivity ($P = 0.0075$, Fisher’s exact test).

The observation that PLK1 overexpression occurs in cancer cells harboring TP53 mutation led some groups to speculate that inhibition of PLK1 may specifically kill TP53 mutant cells (22, 23). Indeed, PLK1 inhibitors specifically kill cells harboring TP53 mutation (22, 23), suggesting TP53 and PLK1 may constitute a synthetic lethal interaction. We find a similar relation between TP53 and PLK1 in human TCGA GBM tumor samples ($P = 0.0099$, Fisher’s exact test). Our method does not find significant correlation between PLK1 overexpression and the mutation status of any gene other than TP53.

DBF4 overexpression has been specifically linked to TP53 status (24). RNA-mediated interference of DBF4 was shown to correlate with the specific growth and reduce survival of melanoma cells (25). Our method found that DBF4 overexpression is correlated with TP53 mutation in TCGA GBM tumor samples ($P = 0.0099$, Fisher’s exact test). TP53 and DBF4 may constitute a synthetic lethal pair, and DBF4 drugging might specifically kill cells harboring TP53 mutation. Our method does not find significant correlation between DBF4 overexpression and the mutation status of any gene other than TP53.

siRNA knockdown of the TP53-associated TCP1 gene resulted in slowed growth in an ovarian carcinoma cell line (26). In a study using 186 breast cancer tumors, TCP1 subunit overexpression was shown to be correlated with TP53 mutation (27). We find significant correlation ($P = 0.0099$, Fisher’s exact test) between TCP1 overexpression and TP53 mutation in TCGA GBM tumor samples. TP53 mutation may create a dependence on the overexpression of TCP1 and TCP1 may present a therapeutic vulnerability in some TP53-driven cancers.

**BUB3** (28), **HSPA14** (HSP60; ref. 29), **TFAM** (30), **GFTP1** (GFAI; ref. 31), **DERL1** (32), **SND1** (33), **ALDH1B1** (34), **RECK** (35), **UGDH** (36), **AOF2** (LSD1; ref. 37), **GADD45G** (38), and **CERK** (ceramide kinase; ref. 39) have also been central genes in at least one cancer study where each was found to be overexpressed in certain cancers. DERL1 overexpression inspired Ran and colleagues (32) to target DERL1 with anti-DERL1 antibodies, which resulted in tumor growth suppression in mice. The UGDH inhibitors gallic acid and quercetin have strong antiproliferative effects in breast cancers overexpressing UGDH (36). siRNA-mediated knockdown of AOF2 (LSD1) slows neuroblastoma cell growth in cells overexpressing AOF2 (37). Repression of CERK in a human adenocarcinoma cell line overexpressing CERK induced apoptosis (40). HSPA14 (HSP60) inhibition can selectively induce apoptosis in tumor cells overexpressing HSPA14 (29). To the best of our knowledge, this is the first time, the overexpression of these genes has been linked to TP53 mutation. Because inhibition of these genes induces effects specific to cancer cells, they may be druggable targets in cancers mutated in TP53.

Subclusters in Figure 2 arise from tumor samples sharing genes with similar TP53 mutation–correlated expression. For example, PLK1, DBF4, AOF2, TCP1, and CERK (defined here as cluster A) cluster together because they have similar expression across all samples. Overexpression of each cluster A gene is associated with a druggable dependence in cancer cells (22, 23, 25, 26, 37, 40), and PLK1 (22), DBF4 (24), and TCP1 (27) are known to be overexpressed specifically in the context of TP53 mutation. Our method identifies groups of tumors that may have a dependence on multiple druggable targets. Tumor dependence on multiple overexpressed druggable genes may be of therapeutic relevance because low-concentration inhibitor cocktails could replace single-agent targeted therapies, resulting in increased therapeutic index (41).

**Mutation-correlated differential expression among subclusters** may also inform therapeutic regimens. For instance, GFTP1, GORASP2, PGRMC2, DERL1, SND1, ALDH1B1, OPRL1, and RECK (defined here as cluster B) are overexpressed in tumors distinct from those with cluster A gene overexpression. Because cluster A gene overexpression is a signature of cluster A gene dependence, cluster A gene inhibitors might inhibit tumors overexpressing cluster A genes more than tumors lacking cluster A gene overexpression. In that case, patients with cluster A signatures and patients with cluster B signatures may benefit from different drugging protocols, which our method highlights.

**IDH1/SYNE1 networks**

In a landmark study, Parsons and colleagues discovered a novel, high-frequency driver mutation in IDH1, highlighting the utility of unbiased genomics experiments (4). Focused studies by many groups confirmed the importance of IDH1 mutation in GBM. Of the 41 mutated genes returned by our method, IDH1 is one of the most studied genes in GBM (Table 1, column 5), which is striking considering its importance in GBM is recently discovered. Our method finds 1,001 genes have drastic over- or underexpression associated with IDH1 mutation status; this IDH1 network is by far the largest network returned by our method (Table 1, column 3). This suggests that IDH1 mutation is associated with an unique GBM (epi)genotype. Indeed, IDH1 mutation is a defining characteristic of the proneural GBM subtype (11) and the glioma CpG island methylator phenotype (12).

Figure 3 is a graph representation of all IDH1 nearest and second-nearest neighbors. In this graph, nodes represent mutated genes, overexpressed oncogenes or GBM survival genes, or underexpressed tumor suppressors returned by our method. These types of coordinated (de)activation can drive cancer, and second-nearest neighbors highlight networks connected by common genes.

We find that TCGA GBM tumors with IDH1 mutation are significantly correlated with the drastic overexpression of several known GBM survival genes (Fig. 3 and Table 2; ref. 18): **MPHOSPH1**, **POLR2F**, **ARHGFE11**, and **AKT3** ($P = 4.1 \times 10^{-2}, 2.8 \times 10^{-3}, 2.8 \times 10^{-3}$, and $2.8 \times 10^{-3}$, respectively). Because IDH1 mutation is a defining characteristic of specific GBM (epi)genotypes, druggable dependencies associated with IDH1 mutation status could be clinically relevant. M phase phosphoprotein 1 (MPHOSPH1) is known to be overexpressed in some bladder cancers (42). Recently, phase I/II trials using MPHOSPH1 peptide epitopes were shown to induce specific cytotoxic T lymphocytes against...
bladder cancers overexpressing MPHOSPH1 (42). Our results suggest that similar approaches may benefit some gliomas mutated in IDH1. AKT3 overexpression was found in a significant fraction of breast and prostate cancers (43) and has been reported as a possible oncogene and a potential glioma survival gene (18). Indeed, oncogene addiction could be considered a type of survival gene dependence. Importantly, AKT3 is a well-studied cancer gene, and inhibitors of AKT3 and other genes in the AKT3 pathway exist (43). Here, we find that drastic overexpression of AKT3 is exclusively and significantly associated with IDH1 mutation. Overexpression of the GBM survival genes POLR2F and ARHGDEF11 are known markers in colon (44) and gall bladder (45) cancer, respectively; unfortunately, we know of no drugs that target these genes. All known GBM survival genes whose drastic overexpression is correlated with mutation status of another gene, and the corresponding mutated genes, are shown in Table 2.

Our method identified several mutation-correlated overexpressed oncogenes and underexpressed tumor suppressors, the majority being significantly associated with IDH1 mutation status (Fig. 3 and Table 3). The underexpression of tumor suppressors RARRES3, DKK3, and MCC was significantly correlated with IDH1 mutation ($P = 8.0 \times 10^{-5}$, $9.0 \times 10^{-3}$, and $2.8 \times 10^{-3}$, respectively); DKK3 and MCC underexpression was exclusively associated with IDH1 mutation. Overexpression of the oncogenes RAF1, MYCN, TET3, and CDC25A was significantly correlated with IDH1 mutation ($P = 2.8 \times 10^{-3}$, $9.0 \times 10^{-3}$, $1.2 \times 10^{-3}$, and $1.2 \times 10^{-3}$, respectively); MYCN, TET3, and CDC25A overexpression was exclusively associated with IDH1 mutation. All known oncogenes whose drastic overexpression, and tumor suppressors whose drastic underexpression is correlated with mutation status of another gene, and the corresponding mutated genes, are shown in Table 3.

Our method finds that 543 genes have drastic over- or underexpression associated with SYNE1 mutation status; this SYNE1 network is the second largest network returned by our method (Table 1, column 3). Similarly, SYNE1 participates in significant mutational co-occurrence more than any other gene; there are 12 mutation–mutation interactions involving SYNE1 (Fig. 3). Also, SYNE1 is the only gene with which MSH6
and MLH1 have complete mutational overlap ($1.1 \times 10^{-5}$ and $2.2 \times 10^{-4}$, respectively); MSH6 and MLH1 are mismatch repair genes whose mutation is known to cause the so-called *mutator phenotype* in GBM (46).

SYNE1 mutation is high frequency in TCGA GBM tumor samples but has not been highlighted in previous studies using TCGA GBM data (Table 1). Similarly, our method does not find any previous correlation between GBM and SYNE1 mutation in the literature (Table 1). SYNE1 mutation is known to influence cerebellar ataxia and has recently been associated with lung, ovarian, and colorectal cancers (47). Our results suggest that SYNE1 mutation is important in TCGA GBM tumor samples and may be important in some glioblastomas in general.

We find that SYNE1 mutation is significantly correlated with the overexpression of several known GBM survival genes (Table 2). *BUB1B* is a chromosome instability gene known to be involved in cancer (48). The aurora B inhibitor hesperadin can prevent kinetochore localization of *BUB1B* and arrest cell-cycle progression (49); hesperadin has not yet been proven effective in cancer clinical trials. We find this known GBM survival gene to be overexpressed in the presence of SYNE1 mutation ($P = 8.6 \times 10^{-4}$), suggesting BUB1B as a potential therapeutic target in some SYNE1-mutated gliomas. *DDX39* is known to be overexpressed in several cancer types (50) and is a known GBM survival gene (18). We suggest that there is possible a connection between these results, in that DDX39 dependency may present as DDX39 overexpression. And, this dependency is significantly correlated for an unidentified reason. For instance, our method also finds that the underexpression of the *MTUS1*, *ZFHX3*, and *SPINT2* tumor suppressors is significantly and exclusively correlated with the mutation status of SYNE1 in TCGA GBM samples ($P = 8.6 \times 10^{-4}$). Other survival genes having overexpression significantly correlated with SYNE1 mutation status include *MPHOSPH1* and *POLR2F* ($P = 6.5 \times 10^{-4}$ and $2.1 \times 10^{-3}$, respectively) and were described above. Our method also finds that the underexpression of the *MTUS1*, *ZFHX3*, and *SPINT2* tumor suppressors is significantly and exclusively correlated with the mutation status of SYNE1 ($P = 2.1 \times 10^{-3}$, $2.1 \times 10^{-3}$, and $4.1 \times 10^{-3}$, respectively). *RAFI* oncogene overexpression is significantly correlated with SYNE1 mutation status ($P = 2.1 \times 10^{-3}$).

**Other considerations**

One important distinction to make, when considering alteration co-occurrence in cancer, is whether identified interactions have true cellular dependence or whether they are correlated for an unidentified reason. For instance, our

### Table 2. Known GBM survival genes that are overexpressed in correlation with the mutation status of specific TCGA GBM genes

<table>
<thead>
<tr>
<th>Mutated gene(s)</th>
<th>GBM survival gene</th>
<th>Known medical relevance</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>ATM, LEMD3, KLF6, IDH1, SYN1</em></td>
<td><em>MPHOSPH1</em></td>
<td>Phase II epitope peptide vaccine</td>
</tr>
<tr>
<td><em>FBXW7, FURIN, IDH1, MAPK9, SYN1</em></td>
<td><em>POLR2F</em></td>
<td>Prognostic marker in colon cancer</td>
</tr>
<tr>
<td><em>FBXW7, FURIN, IDH1, MAPK9, SYN1, TRPM3</em></td>
<td><em>ARHGEF11</em></td>
<td>Marker in gall bladder cancer</td>
</tr>
<tr>
<td><em>ATM, KLF6, LEMD3, SYN1</em></td>
<td><em>BUB1B</em></td>
<td>Aurora B inhibition by Hesperadin can prevent BUB1B kinetochore localization</td>
</tr>
<tr>
<td><em>IDH1</em></td>
<td><em>AKT3</em></td>
<td>Many inhibitors and upstream inhibitors</td>
</tr>
<tr>
<td><em>SYNE1</em></td>
<td><em>DDX39</em></td>
<td>Marker in several cancers</td>
</tr>
</tbody>
</table>

NOTE: *Mutated gene(s)* whose mutation status was correlated with the overexpression of a known GBM survival gene and *Known medical relevance* of the survival gene. Genes that are grouped by a rectangle were exclusively comutated.

### Table 3. Mutation-correlated inactivation of tumor suppressors and activation of oncogenes (as inferred from expression)

<table>
<thead>
<tr>
<th>Mutated gene(s)</th>
<th>Underexpressed tumor suppressor</th>
<th>Overexpressed oncogene</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>FBXW7</em></td>
<td>RARRES3</td>
<td><em>RAFI</em></td>
</tr>
<tr>
<td><em>FURIN</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>IDH1</em></td>
<td>RARRES3, DKK3, MCC</td>
<td><em>RAFI, MYCN, TET3, CDC25A</em></td>
</tr>
<tr>
<td><em>MAPK9</em></td>
<td>RARRES3</td>
<td><em>RAFI</em></td>
</tr>
<tr>
<td><em>TRPM3</em></td>
<td>RARRES3, DRAM</td>
<td><em>KRAS, CRKL</em></td>
</tr>
<tr>
<td><em>SYNE1</em></td>
<td>MTUS1, ZFHX3, SPINT2</td>
<td><em>RAFI</em></td>
</tr>
</tbody>
</table>

NOTE: *Mutated gene(s)* whose mutation status is correlated with *underexpressed tumor suppressors* and *overexpressed oncogenes*. Genes that were exclusively comutated are grouped into single rows *mutated gene(s)*.
method recovered several GBM survival genes whose overexpression was correlated with IDH1 mutation status. But, IDH1 mutation was found to be associated with a broadly altered (epi)genotype in this and other GBM studies. Therefore, IDH1 mutation and survival gene overexpression could be selected for by similar or overlapping hubs from the IDH1 network, but not by each other. In that scenario, the complex networks could vary among patients and cancer types reducing the generalizability of drugging protocols. Furthermore, any inhibitor targeting an overexpressed gene will be limited in efficacy to scenarios where that gene is significantly overexpressed in the patients tumor relative to their healthy tissue.

Elucidating true interaction dependence could also be informative. For instance, if mutation in hypothetical gene A created a strict cellular dependence on the overexpression of hypothetical gene B, then by definition, there would be a requirement for gene B overexpression to precede gene A mutation during cancer progression. This temporal ordering would be required because cells harboring mutation in gene A, but not overexpressing gene B, would be eliminated from the population. In cancer genomics data, this would manifest as a significant correlation between gene A mutation and gene B overexpression, and on an average, a greater number of samples overexpressing gene B, compared with those harboring gene A mutation. The requirement for such temporal ordering could be exploited for prognosis as well as provide an obvious therapeutic target.

Conclusions

In this report, we developed an intuitive and unbiased method to exhaustively interrogate cancer genomics data to identify genes that tumors require for progression and survival. The method identified many genes known to promote GBM pathogenesis and highlighted several genes not previously associated with GBM as potentially important in GBM pathogenesis. In addition, the algorithm identified known druggable cancer-specific dependencies, survival genes, and potential synthetic lethal interactions. And, all observations were identified with patient specificity, which could increase clinical utility.

This algorithm should be a useful complement to existing methods. Because it is exhaustive, and unbiased in that all genes are tested regardless of prior association to disease, our new algorithm may identify novel correlations that add to the existing/emerging picture of gliomas and cancer in general. Furthermore, development of model-free approaches, such as those developed in this study, may be applicable to a wide range of genes and pathways as they do not rely on previously curated pathway or interaction databases.

A useful addition to our algorithm might be to consider site- or domain-specific mutation. Although this is expected to be noisy for most genes, genes with multiple domain-specific functions may influence distinct, mutation-specific regulatory changes. One difficulty in implementing such a strategy would be distinguishing protein functional regions in an automated fashion.

One improvement to our method would be the ability to automatically return known inhibitors for inferred therapeutic vulnerabilities. It is not immediately obvious how this improvement could be implemented, owing to a lack of systematic annotation in the literature; however, assembling the correct drug databases might be one approach. If successful, clinical cancer genomics data would be algorithmic input, and the output could consist of therapeutic vulnerabilities ranked by known druggability.

Important open questions include the origin of drug resistance and the generalizability of synthetic lethal interactions. Most inhibitors targeting a specific driver gene have only modest success, often owing to off-target alterations. Similarly, synthetic lethal killing of tumor cells with generalizability has yet to be shown, suggesting the potential existence of a synthetic lethal network. Therefore, a comprehensive list of compensatory alterations that cause drug resistance or facilitate viability in the presence of targeted synthetic lethality may be useful. The information imparted from such a compendium could allow clinicians to cut cancer off at the pass. To that end, the combined effort of high-throughput cancer (epi)genomics experiments and complementary bioinformatics approaches is indispensable.

Disclosure of Potential Conflicts of Interest

Under agreements between the Johns Hopkins University and Agios Pharmaceuticals, R. Karchin is entitled to a share of the royalties received by the University on sales of products related to IDH genes. D.L. Masica declared no potential conflicts of interest.

Acknowledgment

The authors thank Dr. Bert Vogelstein for his critical reading of the manuscript.

Grant Support

This work was funded by NIH National Cancer Institute grant CA135877 and NSF DBI CAREER award 0845275 to R. Karchin.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received January 20, 2011; revised April 13, 2011; accepted May 1, 2011; published OnlineFirst May 9, 2011.

References


Masica and Karchin


Correlation of Somatic Mutation and Expression Identifies Genes Important in Human Glioblastoma Progression and Survival

David L. Masica and Rachel Karchin

Cancer Res 2011;71:4550-4561. Published OnlineFirst May 9, 2011.

Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-11-0180

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2011/05/09/0008-5472.CAN-11-0180.DC1

Cited articles
This article cites 50 articles, 18 of which you can access for free at:
http://cancerres.aacrjournals.org/content/71/13/4550.full#ref-list-1

Citing articles
This article has been cited by 6 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/71/13/4550.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://cancerres.aacrjournals.org/content/71/13/4550.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
Rightlink site.